Illumina Platform (ILMN) Price to Earnings Ratio

Corporate emblem and logo of Illumina Corp (ILMN)

AI algorithms and robots are automating genome sequencing, yet the P/E dynamics of Illumina, Inc. (ILMN) reflect volatile expectations, with the ratio currently standing at 34.60. Business resilience is underpinned by unique patents and stringent antitrust oversight. Profit scalability is driven by new sequencing platforms that boost demand for high-margin consumables while reducing laboratory costs.

ILMN Illumina: Price to Earnings Ratio in the range 07/04/2022 - 11/16/2026

Analytical breakdowns for Illumina, Inc.

- price and consensus price forecast:
Summary company analysis:Illumina, Inc.
Manufactured product of Illumina, Inc.

To minimize fundamental risks, investors should select assets with a justified value-to-yield ratio. The P/E ratio is calculated as market capitalization divided by net income, determining the investment payback period. For Illumina, Inc. (ILMN), which has restored cash flows following asset restructuring, this metric confirms the efficiency of equipment sales. By analyzing the company's forward P/E, one can determine the extent of the premium paid for the business.

Analysis of competing companies

Agilent (A) - Business Payback Period|Price to Earnings Ratio DGX (questdiagnostics.com)|Price to Earnings Ratio EXAS (Exact Sciences)|Revvity Inc - Price to Earnings Ratio|Business Payback Period Bio-Rad Laboratories (BIO)|NNNN - Price to Earnings Ratio|Business Payback Period Sotera Health Corp SHC|QDEL: P/E Multiple|OPK - Business Payback Period|Price to Earnings Ratio CareDx|maravai.com (MRVI) - Business Payback Period|P/E Multiple FLGT|Market Price to Net Income Ratio LAB|cytekbio.com - Price to Earnings Ratio|Company Value to Net Income OSUR|exagen.com - P/E Multiple|MDXH (MDxHealth SA) - Price to Earnings Multiple|LUCD: P/E Multiple|Market Cap to Earnings Prenetics Global (PRE)|IMDX (Insight Molecular Diagnostics) - P/E Multiple|Trinity Biotech (TRIB) - Business Payback Period|P/E Multiple PRPH|AIMD (Ainos, Inc.) - Company Value to Net Income|P/E Multiple CODX (codiagnostics.com)|Market Price to Net Income Ratio HSCS (HeartSciences)|Biomerica Inc - P/E Multiple|CDIO (cardiodiagnosticsinc.com) - Price to Earnings Multiple|ONCO (Onconetix) - Price to Earnings Ratio|Market Cap to Earnings viraxbiolabs.com (VRAX)|BJDX (Bluejay Diagnostics Inc) - P/E Multiple|Market Cap to Earnings Aspira Women's Health, Inc. AWH|Price to Earnings Ratio AXDX (Accelerate Diagnostics, Inc)|CENTOGENE, N.V. - Price to Earnings Multiple|Enzo Biochem, Inc. - Price to Earnings Ratio|FRES - Price to Earnings Ratio|GENE - Price to Earnings Ratio|Company Value to Net Income ME (23andMe)|PMD: P/E Multiple